In conclusion, since over-expression of HSP27 induces cancer cells resistant to many cancer treatments and HSP27 expression correlates with poor survival of lung tumor patients, especially those with lung adenocarcinoma, inhibition of HSP27 is a good strategy for sensitization of NSCLC in combination with other anticancer drugs. Here, HSPB1 is linked to non-small cell lung carcinoma.